Effects of Cerivastatin on Human Arterial Smooth Muscle Cell Proliferation and Migration in Transfilter Cocultures
Authors:
- Dorothea I. AxelDADorothea I. Axel
- Reimer RiessenRRReimer Riessen
- Heike RungeHRHeike Runge
- Richard ViebahnRVRichard Viebahn
- Karl R. KarschKKKarl R. Karsch
- 1 April 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 35 (4) , 619-629
Abstract
Statins competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity reducing mevalonate synthesis. In this study, antiproliferative and antimigratory effects of the new compound cerivastatin were analyzed and compared with classic statins of the first and second generation using mono- and cocultures of human arterial smooth muscle (haSMC) and endothelial (haEC) cells. Effects on the mitotic index and mitochondrial activity of haEC and haSMC monocultures were tested using BrdU enzyme-linked immunosorbent assay (ELISA) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) tests, respectively. In lactate dehydrogenase (LDH) assays, cytotoxicity of statins was studied. Transfilter cocultures were performed for 14 days to evaluate haSMC growth under the stimulatory effect of proliferating haEC, which release growth factors [e.g., platelet-derived growth factor (PDGF)]. The hydrophobic statins simvastatin, lovastatin, and atorvastatin significantly inhibited haSMC and haEC growth in monocultures at 0.5-50 μM. However, most potent effects were exerted by cerivastatin in 10- to 30-fold lower doses without any significant cytotoxicity. More important, cerivastatin showed also significant effects on haSMC proliferation and migration in transfilter cocultures at extremely low doses (IC50, 0.04-0.06 μM), even when applied exclusively to the endothelial side and in the presence of low-density lipoprotein (LDL). Addition of mevalonate abolished the effects of cerivastatin completely. Even in the presence of growth-stimulating haEC and LDL, cerivastatin was found to be the most potent inhibitor of haSMC proliferation and migration in doses that also can be reached in human serum after oral drug administration. The results support the concept that statins seems to influence additional cellular mechanisms beyond cholesterol reduction, which might also have a relevance for the prevention of restenosis.Keywords
This publication has 54 references indexed in Scilit:
- AtorvastatinDrugs, 1997
- Effects of flwastatin on growth of porcine and human vascular smooth muscle cells in vitroThe American Journal of Cardiology, 1995
- Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitorsThe American Journal of Cardiology, 1995
- Lovastatin Inhibits Proliferation and Differentiation and Causes Apoptosis in Lipopolysaccharide-Stimulated Murine B CellsBiochemical and Biophysical Research Communications, 1995
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in HumansThe Journal of Clinical Pharmacology, 1992
- Prevention of restenosis by lovastatin after successful coronary angioplastyAmerican Heart Journal, 1991
- Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and LovastatinThe Journal of Clinical Pharmacology, 1990
- Regulation of the mevalonate pathwayNature, 1990